Tornier N.V.  

(Public, NASDAQ:TRNX)   Watch this stock  
Find more results for TRNX
16.42
-0.07 (-0.42%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.38 - 16.64
52 week 14.53 - 23.54
Open 16.60
Vol / Avg. 214,666.00/198,698.00
Mkt cap 696.50M
P/E     -
Div/yield     -
EPS -0.70
Shares 42.42M
Beta     -
Inst. own 80%
Aug 5, 2013
Q2 2013 Tornier NV Earnings Release Add to calendar
Jun 27, 2013
Tornier NV Annual Shareholder Meeting - 7:30AM EDT - Add to calendar
May 15, 2013
Tornier NV at Bank of America Merrill Lynch Health Care Conference
May 7, 2013
Q1 2013 Tornier NV Earnings Conference Call
May 6, 2013
Q1 2013 Tornier NV Earnings Release
Feb 27, 2013
Tornier NV at RBC Capital Markets' Healthcare Conference
Feb 21, 2013
Q4 2012 Tornier NV Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -8.34% -7.84%
Operating margin -5.58% -10.42%
EBITD margin - 11.84%
Return on average assets -4.24% -3.73%
Return on average equity -6.41% -5.19%
Employees 916 -
Carbon Disclosure Rating - -

Address

Fred. Roeskestraat 123
AMSTERDAM, 1076 EE
Netherlands
+31-20-5771177 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Tornier N.V. (Tornier) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. Tornier refers to these surgeons as extremity specialists. The Company sells to this extremity specialist customer base a broad line of joint replacement, trauma, sports medicine and biologic products to treat extremity joints. In certain international markets, it also offers joint replacement products for the hip and knee. The Company sells over approximately 100 product lines in approximately 40 countries. The Company�s principal products are organized in four categories: upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and biologics, and large joints and other. The Company�s geographic regions consist of the United States, France and other areas. On October 4, 2012, the Company acquired OrthoHelix.

Officers and directors

David H. Mowry President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Shawn T. McCormick Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Terry M. Rich Senior Vice President - U.S. Commercial Operations
Age: 45
Bio & Compensation  - Reuters
Gregory Morrison Global Vice President - Human Resources
Age: 49
Bio & Compensation  - Reuters
Kevin M. Klemz Vice President, Chief Legal Officer, Secretary
Age: 51
Bio & Compensation  - Reuters
Stephan Epinette Vice President - International Commercial Operations
Age: 42
Bio & Compensation  - Reuters
Sean D. Carney Non-Executive Independent Chairman of the Board
Age: 44
Bio & Compensation  - Reuters
Kevin C. O'Boyle Interim Non-Executive Independent Vice Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Alain Tornier Non-Executive Director
Age: 66
Bio & Compensation  - Reuters
Richard B. Emmitt Non-Executive Independent Director
Age: 68
Bio & Compensation  - Reuters